scholarly article | Q13442814 |
P50 | author | Hao Zeng | Q88623996 |
P2093 | author name string | Peng Zhao | |
Jiandong Liu | |||
Pengfei Shen | |||
Guangxi Sun | |||
Xingming Zhang | |||
Jinge Zhao | |||
Junru Chen | |||
Jindong Dai | |||
P2860 | cites work | Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. | Q45930559 |
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for hi | Q46259659 | ||
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study | Q46616101 | ||
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study | Q46817220 | ||
Cancer statistics, 2018. | Q47191906 | ||
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. | Q48535376 | ||
Avoiding Undertreatment of Aggressive Prostate Cancer by Early Use of Chemotherapy. | Q51345317 | ||
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study. | Q53041535 | ||
Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer? | Q54566799 | ||
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. | Q55067996 | ||
Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence | Q73146858 | ||
Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone | Q79823525 | ||
Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy | Q80744531 | ||
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 | Q88291250 | ||
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data | Q26771537 | ||
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 | ||
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916 | Q33432475 | ||
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials | Q34013808 | ||
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer | Q34296696 | ||
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer | Q34487137 | ||
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer | Q35967139 | ||
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. | Q36480632 | ||
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial | Q36707077 | ||
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer | Q37439463 | ||
Treatment strategies for high-risk locally advanced prostate cancer | Q37671592 | ||
What is the pathophysiology of a hormone-resistant prostate tumour? | Q37937865 | ||
High-risk prostate cancer: from definition to contemporary management | Q37990230 | ||
Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective | Q38060845 | ||
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial | Q38392753 | ||
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. | Q38706310 | ||
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial | Q40885260 | ||
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. | Q42864027 | ||
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. | Q44114886 | ||
Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer | Q44809404 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | chemotherapy | Q974135 |
P304 | page(s) | 9061-9070 | |
P577 | publication date | 2018-12-13 | |
P1433 | published in | OncoTargets and Therapy | Q7092081 |
P1476 | title | The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis | |
P478 | volume | 11 |
Search more.